Sponsored
Documentation
Vendor-supplied data
COA stated as available
Not independently documented
Checked
Jul 18, 2026
Recovery / Regeneration
Buy GLOW (blend) – Vendors, Prices, Testing and Evidence
Also known as: GLOW blend · GHK-Cu / BPC-157 / TB-500 blend
Evidence grade D — AnecdotalRisk flag
Short answer
A research-market blend combining GHK-Cu, BPC-157, and TB-500, marketed for recovery and skin. Blends like this have no evidence base of their own; at best they inherit the thin, mostly preclinical data on each separate component.
Where can you buy GLOW (blend)?
Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.
What is known?
GLOW is not a single compound but a fixed combination product, most commonly marketed as a blend of three research peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic peptide fragment), and TB-500 (a fragment related to thymosin beta-4). It is sold for soft-tissue recovery, skin, and 'wellness'. There is no standardized formula, and ratios differ between vendors.
What is not established?
None for the blend. No clinical trials have studied this GHK-Cu / BPC-157 / TB-500 combination in humans for safety or effectiveness. The individual components also lack robust human evidence: GHK-Cu's human data is largely limited to topical cosmetic use, and BPC-157 and TB-500 have essentially no adequately controlled human trials. Combining unproven agents does not create evidence — it removes the ability to tell which ingredient is responsible for any effect.
Safety
The safety of the blend is unknown. No formal human safety data exist for the combination, and fixed-ratio blends make it harder to identify the source of any adverse reaction or to adjust exposure to a single ingredient. Products are sold as research chemicals with variable composition and purity, adding contamination and mislabeling risk on top of the unknowns of each peptide.
Regulatory status
Not an approved medicine anywhere. GLOW is a research-market blend sold under 'research use only' labeling and is not approved by the FDA, EMA, or any regulator. Its individual components (GHK-Cu, BPC-157, TB-500) are themselves unapproved as drugs, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list.
Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.
Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.
Vendor comparison
Buy GLOW (blend): compare vendors
The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.
Affiliate disclosure: This page contains affiliate links. peptides.cx may receive a commission when a purchase is made through one of these links. Evidence ratings, safety summaries and editorial content are produced independently from vendor relationships.
What is it?
GLOW is not a single compound but a fixed combination product, most commonly marketed as a blend of three research peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic peptide fragment), and TB-500 (a fragment related to thymosin beta-4). It is sold for soft-tissue recovery, skin, and 'wellness'. There is no standardized formula, and ratios differ between vendors.
Research and evidence
GLOW is not a single compound but a fixed-ratio blend of research peptides, most commonly sold as a combination of three: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic peptide fragment), and TB-500 (a fragment related to thymosin beta-4). It is marketed on the research-chemical market for soft-tissue recovery, skin, and general "wellness." There is no standardized formula behind the name, and the ratio of ingredients differs from vendor to vendor. Understanding GLOW therefore means understanding that it is a convenience stack of three separate, individually unapproved peptides rather than a studied product in its own right.
The honest evidence picture is stark: there is none for the blend itself. No clinical trials have studied this GHK-Cu / BPC-157 / TB-500 combination in humans for either safety or effectiveness, and the individual components are themselves thinly evidenced — GHK-Cu's human data is largely limited to topical cosmetic use, while BPC-157 and TB-500 have essentially no adequately controlled human trials. Combining three unproven agents does not create evidence; it removes the ability to tell which ingredient is responsible for any effect. A fixed-ratio blend has no evidence base of its own, and at best it inherits the thin, mostly preclinical data attached to each separate peptide. This is why GLOW carries the lowest evidence grade on the site.
That structure also makes safety harder to reason about. With several agents combined at fixed proportions, any adverse reaction is difficult to attribute to a specific ingredient, and exposure to a single component cannot be adjusted independently. No formal human safety data exist for the combination, and products sold as research chemicals carry additional contamination, mislabeling, and purity risks on top of the unknowns of each peptide. GLOW is not an approved medicine anywhere; it is sold under "research use only" labeling, and two of its components, BPC-157 and TB-500, are prohibited in sport under the World Anti-Doping Agency (WADA) list. This page is an educational reference, not medical advice, and it provides no dosing, administration, or sourcing guidance.
Evidence grade: D
None for the blend. No clinical trials have studied this GHK-Cu / BPC-157 / TB-500 combination in humans for safety or effectiveness. The individual components also lack robust human evidence: GHK-Cu's human data is largely limited to topical cosmetic use, and BPC-157 and TB-500 have essentially no adequately controlled human trials. Combining unproven agents does not create evidence — it removes the ability to tell which ingredient is responsible for any effect. Only indirect. Each component has some preclinical (mostly rodent or in vitro) literature, but there are no animal studies of this specific fixed-ratio blend, and preclinical results for the components have not been confirmed in humans.
Human evidence
None for the blend. No clinical trials have studied this GHK-Cu / BPC-157 / TB-500 combination in humans for safety or effectiveness. The individual components also lack robust human evidence: GHK-Cu's human data is largely limited to topical cosmetic use, and BPC-157 and TB-500 have essentially no adequately controlled human trials. Combining unproven agents does not create evidence — it removes the ability to tell which ingredient is responsible for any effect.
Animal and preclinical evidence
Only indirect. Each component has some preclinical (mostly rodent or in vitro) literature, but there are no animal studies of this specific fixed-ratio blend, and preclinical results for the components have not been confirmed in humans.
Proposed mechanisms
- No mechanism has been characterized for the blend as a whole; any rationale is extrapolated from the individual peptides
- GHK-Cu is studied mainly in vitro and in topical cosmetics for effects on collagen and wound-healing signaling
- BPC-157 is proposed, largely from rodent studies, to influence angiogenesis and tissue-repair pathways
- TB-500 is proposed to affect cell migration and actin dynamics, again mainly from preclinical work
- Combining three agents makes it impossible to attribute any observed effect or harm to a specific component
Safety concerns and known side effects
The safety of the blend is unknown. No formal human safety data exist for the combination, and fixed-ratio blends make it harder to identify the source of any adverse reaction or to adjust exposure to a single ingredient. Products are sold as research chemicals with variable composition and purity, adding contamination and mislabeling risk on top of the unknowns of each peptide.
- Not characterized in humans; no reliable adverse-event data for the blend
- Injection-site reactions reported anecdotally with the individual peptides
- Unknown risks from combining multiple unapproved peptides
- Contamination, mislabeling, and dose-uncertainty risks from research-chemical sourcing
Regulatory status
Not an approved medicine anywhere. GLOW is a research-market blend sold under 'research use only' labeling and is not approved by the FDA, EMA, or any regulator. Its individual components (GHK-Cu, BPC-157, TB-500) are themselves unapproved as drugs, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list.
Frequently asked questions about GLOW (blend)
- What is in the GLOW peptide blend?
- GLOW is most commonly a fixed blend of three research peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic peptide fragment), and TB-500 (a fragment related to thymosin beta-4). There is no standardized formula, so the exact ingredients and ratios can differ between vendors.
- Is there any evidence for the GLOW blend?
- No. There are no clinical trials of the GHK-Cu / BPC-157 / TB-500 combination in humans for safety or effectiveness. A blend has no evidence base of its own; at best it inherits the thin, mostly preclinical data on each separate component, and combining them removes the ability to tell which ingredient does what.
- Does the GLOW peptide blend work?
- There is no reliable human evidence that it does. The individual peptides are themselves poorly evidenced — GHK-Cu's human data is mostly from topical cosmetic use, and BPC-157 and TB-500 have essentially no adequately controlled human trials. Anecdotal reports are not a substitute for controlled studies.
- Is the GLOW blend approved or legal?
- GLOW is not an approved medicine anywhere. It is sold under "research use only" labeling and is not authorized by the FDA, EMA, or any regulator. Its individual components are also unapproved as drugs, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list.
- Is the GLOW blend safe?
- Its safety is unknown. No formal human safety data exist for the combination, and a fixed-ratio blend makes it harder to identify the source of any adverse reaction or to adjust a single ingredient. Research-chemical products add contamination, mislabeling, and purity risks. This is educational information, not medical advice.
- What is the difference between GLOW and KLOW?
- Both are research-market peptide blends. KLOW is essentially the GLOW combination (GHK-Cu, BPC-157, TB-500) with the anti-inflammatory peptide KPV added, and sometimes LL-37 as well. Neither blend has any human evidence of its own.
- Where can I buy GLOW (blend) and compare vendors?
- Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.
Common discussion areas
That 'GLOW' is a convenience blend of GHK-Cu, BPC-157, and TB-500 rather than a studied compoundAnecdotal reports about skin and soft-tissue recoveryFrustration that fixed blends prevent knowing which component does whatWADA-prohibited status of BPC-157 and TB-500 for athletes
Sources
No suitable primary study or review specific to this entry was identified during the last editorial review.
Editorial review and transparency
- Written by
- peptides.cx Editorial Team
- Scientific reviewer
- No named medical reviewer is currently assigned
- Last editorial review
- July 18, 2026
- Last vendor check
- July 18, 2026
- Review method
- Source review, claim verification, vendor-data separation and regulatory-context review.
- Commercial disclosure and conflicts
- Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.